Empagliflozin improves cardiac energetics during ischaemia/reperfusion by directly increasing cardiac ketone utilisation.
Dylan ChaseThomas R EykynMichael J ShattockYu Jin ChungPublished in: Cardiovascular research (2023)
Heart failure remains a huge clinical burden. Clinical trials of SGLT2 inhibitors in patients with diabetes and heart failure have reported significant cardio-protection from EMPA treatment that appears independent of improved glycaemic control. The direct cardiac effect of EMPA in modulating ketone metabolism observed in this study raises the potential for EMPA to be used as a therapy for heart failure in both diabetic and non-diabetic patients alike.
Keyphrases
- heart failure
- left ventricular
- clinical trial
- type diabetes
- cardiac resynchronization therapy
- acute myocardial infarction
- acute heart failure
- atrial fibrillation
- signaling pathway
- randomized controlled trial
- coronary artery disease
- combination therapy
- risk assessment
- acute ischemic stroke
- climate change
- replacement therapy
- subarachnoid hemorrhage